Wortmannin

Catalog No.S2758 Synonyms: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 21 Publications

5 Customer Reviews

  • L3.6pl cells at 6,000 cells per well were incubated in MEM with 5% FBS in triplicate in a 96-well culture plate and then treated alone with 5 umol/L BMS-777607, 10 umol/L wortmannin, or with BMS-777607 in combination with individual inhibitors. Polyploidy was examined under BK71 Olympus microscope and photographed 72 hours after treatment.

    Mol Cancer Ther 2014 13(1), 37-48. Wortmannin purchased from Selleck.

    The effects of KITL on the differentiation of stem Leydig cells. Seminiferous tubules were cultured in the presence of various concentrations of KITL (K) without (C) or with PI3K inhibitor wortmannin (W) for 21 days. Panel A, KITL (0-100 ng/ml); Panel B, KITL (K) alone or with W (100 nM), K1 = KITL 1 ng/ml, K100 = 100 ng/ml. Medium testosterone (T) levels were measured. Mean ± SEM, n = 4-8. Identical letters indicate no significant difference between two groups at P < 0.05. W:Wortmannin

    Mol Cell Endocrinol, 2017, 444:1-8. Wortmannin purchased from Selleck.

  • Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

    Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

  • Cell growth inhibition of non-small cell lung carcinoma (NSCLC) by inhibitor of phosphoinositide 3-kinases (PI3Ks) Wortmannin. NCI-H460 and its multi-drug resistant (MDR) counterpart NCI-H460/R were subjected to Wortmannin. According to the results obtained, the effect of Wortmannin is dependent on the existence of MDR in the range of tested concentrations.

    2014 Dr.Milica Pesic from Institute for Biological Research. Wortmannin purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 MkDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXWyMlUh|ryP MWCxMVQh\A>? NHrsVGZFVVOR M4LBNoVvcGGwY3XzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25idILlZZRu\W62IIfpeIghfGGvb4jp[oVv M{jkUlI2PDlyM{iz
H1703 NUPNNFd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXuyMlUh|ryP MmXYNU01KGR? NFT5cZJFVVOR NUOycotM\W6qYX7j[ZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD0doVifG2nboSge4l1cCC2YX3vfIln\W5? NWXCVYt5OjV2OUCzPFM>
HUVECs MnvUR5l1d3SxeHnjbZR6KEG|c3H5 MVGxNFAhdk1? NI[2OnozPCCq MUfheJRmdnWjdHXzJJRp\SCjYoLv[4F1cX[nIHXm[oVkfHNib3[gZ4FtgWOxc3nuJI9vKF[UST3pcoR2[2WmIHP5eI91d3irY3n0fS=> M{XzUlI2PDVyMUi2
APRE-19 NFHKcZlCeG:ydH;zbZMhSXO|YYm= NIfZXYY2KM7:TR?= NWLOU|FtOjRiaB?= NH;T[Y5i[m:uaYPo[ZMhTkycLX3l[IlifGWmIIDyc{1{fXK4aY\hcE9idnSrLXHwc5B1d3OrczDhZ5Rqfmm2eR?= MYCyOVMzQTZzNx?=
MDA-MB-231 NF\zbYRCeG:ydH;zbZMhSXO|YYm= MmnrNeKh|ryPwrC= M4\ydFQ5KGh? NYS0NXd[TE2VTx?= MUPk[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygeJJm[XSnZDD3bZRpKDJ3IN88UUBw\iCIMTDvdkBHOiEEoB?= M361W|I2OzByOUOy
MCF7 MVLGeY5kfGmxbjDBd5NigQ>? M4HPflExOCCwTR?= MmCwNlQhcA>? Moqx[YxqdWmwYYTld{BGOi2rbnT1Z4VlKEGURT3MeYMh[WO2aY\peJk> MXKyOVE4OjV3Nx?=
HT-29  NH;hNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rQT|EvPcLiwsXN M17NdFk3KGh? NHrEWZBl\WO{ZXHz[ZMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJIlvcGmkaYTl[EBjgSCNWV7B Mnv6NlUxOTJzMkO=
MO59K  MoPxR5l1d3SxeHnjbZR6KEG|c3H5 MYW1xsDPxE1? MkjrO{Bl MkXpSG1UVw>? MX\lcohidmOnczD0bIUh[3m2b4TvfIlkcXS7IH;mJIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? NHXHRmQzPDl3M{W2NS=>
MO59J M3vYd2N6fG:2b4jpZ4l1gSCDc4PhfS=> Mo\nOeKh|ryP MnjJO{Bl MlXhSG1UVw>? MVXlcohidmOnczD0bIUh[3m2b4TvfIlkcXS7IH;mJIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? NXvYOG1LOjR7NUO1OlE>
MO59K  MX;BdI9xfG:|aYOgRZN{[Xl? M1XVPFExKM7:TR?= MmrXNlQhcA>? MljnSG1UVw>? NITCN2tqdmO{ZXHz[ZMhfGinIFTTRkBt\X[nbDDpcoR2[2WmIHL5JIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? NXLkVoNMOjR7NUO1OlE>
MO59J MmPpRZBweHSxc3nzJGF{e2G7 Ml;pNVAh|ryP MW[yOEBp MUHEUXNQ NWDJUnpocW6lcnXhd4V{KHSqZTDEV2IhdGW4ZXygbY5lfWOnZDDifUBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw M1[yS|I1QTV|NU[x
HepG2 NEjEbm1HfW6ldHnvckBCe3OjeR?= NELlNGIyODBibl2= NHnJVXAxNjViaB?= NVK4NWI{TE2VTx?= M3i2[YJtd2OtczDNRU1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44> NWTB[YZVOjR6NkOzOVA>
A549  MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXGzJOK2VcLi MYWyJIg> MlPKd5VxeHKnc4Pld{Bx\W2ndILlfIVlNWmwZIXj[YQhSWu2IHHu[EBIW0t|zsKgZYN1cX[jdHnvckwhWy2yaHHz[UBienKnc4SsJINmdGxiYYDvdJRwe2m|IHHu[EBk[XOyYYPlMVMh[WO2aY\heIlwdg>? MWqyOFg1Pzh4Mx?=
A549  MX\GeY5kfGmxbjDBd5NigQ>? MonmNVDDqM7:bdMg NIe0RmEyPiCq NVLTfmg3TE2VTx?= NEHwfZRud2S3bHH0[ZMhfGinIFnBWkBz\XCuaXPheIlwdiCjbnSgZ4F2e2W|IILleIVvfGmxbjDv[kBPWCCrbjD0bIUhdnWlbHX1d{4> MYKyOFgxOjFzMR?=
SK-N-LO MmnjSpVv[3Srb36gRZN{[Xl? Mom3NVAxKG6P M3jxWlAvPSCq NUPkfWJ6\GWlcnXhd4V{KHSqZTDzeIlufWyjboSg[YZn\WO2czDv[kBud3KyaHnu[UBwdiCDa4SgdIhwe3Cqb4L5cIF1cW:w M2DVb|I1PjV2NkC2
HL-60 NGOzfplHfW6ldHnvckBCe3OjeR?= MlLLNE4yyqEQvF2= NHjaVXI4OiCq MmjYZoxw[2u|IHThd4F1cW6rYj3pcoR2[2WmIHPlcIwh\GmoZnXy[Y51cWG2aX;u M3TxT|I1PjB5Mkez
HepG2  MUTGeY5kfGmxbjDBd5NigQ>? M4P0SlIxOCCwTR?= M3jldFAvPSCq Ml3EZZR1\W63YYTld{BHd3iRIIDoc5NxcG:{eXzheIlwdg>? MoPmNlQ2OzVzOUK=
H520 NEDSNZlHfW6ldHnvckBCe3OjeR?= M1T3T|ExyqEQvF2= MUixJIg> NX\kRmxITE2VTx?= M3zsboRm[3KnYYPld{Bk\WyudXzhdkBxcG:|cHjvMWFMXCCycn;0[YlvKGyndnXsdy=> NULl[VZKOjR2NEe5N|U>
H1975 NGj5UpRHfW6ldHnvckBCe3OjeR?= MmWwNVDDqM7:TR?= MlzrNUBp NWTFfJJFTE2VTx?= M4PFNIRm[3KnYYPld{Bk\WyudXzhdkBxcG:|cHjvMWFMXCCycn;0[YlvKGyndnXsdy=> NIL0bHczPDR2N{mzOS=>
MG-63 M3\ueGFxd3C2b4Ppd{BCe3OjeR?= NFnhXlMyOCEEtV2= M1G4blEzKGh? MnXF[Y5p[W6lZYOgSHAucW6mdXPl[EBieG:ydH;zbZM> MmnRNlQ{PTh|MEG=
5637 NYH0S3p{SXCxcITvd4l{KEG|c3H5 NU\QPFY4OTEEoN88US=> M3jKXlQxKG2rbh?= NVLFTJdqemW4ZYLz[ZMheDJzV1HGNUBmgHC{ZYPzbY9vNCCFRFug[ZhxemW|c3nvckwh[W6mIHPlcIwhcW6qaXLpeIlwdiCrbnT1Z4VlKGK7IH\1Z49q\GGw NUDtdm5bOjR|M{O4Olg>
HEK-293 MX3GeY5kfGmxbjDBd5NigQ>? NX7Ydo5POTVybl2= M2P4OlE3KGh? NVXtb25ZTE2VTx?= MoT5[IVkemWjc3XzJGNTXCCjY4Tpeol1gQ>? M1rTZVI1OzJ2M{[2
SW480  MnzKSpVv[3Srb36gRZN{[Xl? NYfXV2ViOTVybl2= Mn62NlAhcA>? MnnRSG1UVw>? NGD4THlz\WS3Y3XzJINmdGy3bHHyJIFk[3WvdXzheIlwdiCxZjFOtk1k[XSnbnnu Ml3NNlQ{OjR|Nk[=
HepG2 MlfRSpVv[3Srb36gRZN{[Xl? NXT3cXBTOTByIH7N NV;rTZZWOjRiaB?= Ml\ZZZR1\W63YYTld{B1cGViY3;sc45q\XNib3[geIhmKHS3bX;yJINmdGy|IIfpeIghfXC{ZXf1cIF1cW:wIH;mJGFsfDF? NWDQTFFWOjR{OUe1NVA>
HCT 116  M37remZ2dmO2aX;uJGF{e2G7 NI\ybIUyODBibl2= MmfJNlQhcA>? MUTheJRmdnWjdHXzJJRp\SClb3zvcolmeyCxZjD0bIUhfHWvb4KgZ4VtdHNid3n0bEB2eHKnZ4XsZZRqd25ib3[gRYt1OQ>? NGOzW4kzPDJ7N{WxNC=>
BEL/FU Mmr6SpVv[3Srb36gRZN{[Xl? NID3WHAyKG2P NV7xc|FxOjRiaB?= Ml2w[IVkemWjc3XzJJBzd3SnaX6gcIV3\Wy|IH;mJJRp\SCSSUPLM2FsfCCyYYToe4F6 MmLBNlQzOzJyOUm=
Huh7  M3viNWZ2dmO2aX;uJGF{e2G7 Mlz6N:Kh|ryP M1PoVFEhcA>? NHnlSVVz\WS3Y3XzJJRp\SC4aYL1d{BmdnS{eTDpcpRwKHSqZTDj[Yxtew>? MUSyOFE5PDF7Nh?=
A-375 MXPBdI9xfG:|aYOgRZN{[Xl? M1HXZ|QwQCEQvF2= NV;HZXV3OjRiaB?= MUXlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li Mnq5NlQyOTNzN{O=
A-375-TS  MYPBdI9xfG:|aYOgRZN{[Xl? Ml;POE85KM7:TR?= NXqw[pFIOjRiaB?= NGPwTJNmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg MUmyOFEyOzF5Mx?=
Mel-HO NUjoXoo1SXCxcITvd4l{KEG|c3H5 M2\UfVQwQCEQvF2= M{fURVI1KGh? MXTlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li NW\DWHhwOjRzMUOxO|M>
Mel-HO-TS NFu2[WtCeG:ydH;zbZMhSXO|YYm= NITSc2w1NzhizszN NFHHengzPCCq M4G2VIVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= MWKyOFEyOzF5Mx?=
MeWo MV;BdI9xfG:|aYOgRZN{[Xl? M4HIWVQwQCEQvF2= M1\xSlI1KGh? M37J[4VvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= MYOyOFEyOzF5Mx?=
Mel-2a M4DIT2Fxd3C2b4Ppd{BCe3OjeR?= NEXocZg1NzhizszN MYOyOEBp NVeyeVUz\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> Moq4NlQyOTNzN{O=
MDA-MB-231 MV;GeY5kfGmxbjDBd5NigQ>? MXmw5qCUPDByIH7N NYTuXnBiPCCq NVvGToVQe3WycILld5NmeyCDa4SgdIhwe3Cqb4L5cIF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M1LlPFIzQTB4MkW5
MDA-MB-231 MYjGeY5kfGmxbjDBd5NigQ>? NFzBN5U1ODBibl2= MmfpOEBp Mon3[IVkemWjc3XzJG1OWC17IHHu[EBKVC16IIDyc5RmcW5iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnT5NlI6ODZ{NUm=
Jurkat M{[xZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXiwMlI2NTFwMkWg{txO NUDK[GpyOjRxNEigbC=> MX\EUXNQ M3i1[4lvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLTDk[ZBmdmSnboSgcYFvdmW{ MnPHNVk4PTdzOEW=
Namalwa M2e0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPGN2QxNjJ3LUGuNlUh|ryP MUCyOE81QCCq Ml;ySG1UVw>? MXzpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? NF\nWo0yQTd3N{G4OS=>
Jurkat NXGx[4pOSXCxcITvd4l{KEG|c3H5 MkTBNE4zPS1zLkK1JO69VQ>? MX6yOE81QCCq NX3PbZJvTE2VTx?= NWfRZWhVcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz MoS3NVk4PTdzOEW=
Namalwa MlHNRZBweHSxc3nzJGF{e2G7 Ml\LNE4zPS1zLkK1JO69VQ>? MkTHNlQwPDhiaB?= M3;NOWROW09? MofpbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy NFntfIcyQTd3N{G4OS=>
K562 NHO4VZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS2NlQhcA>? NVHBco9kUUN3ME2yOeKyOC5zNDDuUS=> MWGxPVY3OjN4MR?=
SW1990 MkGzSpVv[3Srb36gRZN{[Xl? MX[wMlAyNTFizszN NH74OGoyKGh? MWjpcohq[mm2czDIRU1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44> NHfHU5MyQTR4OUCyNC=>
RT112  NV3FflBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fEblExyqEQvF2= MYeyOEBp M2DrXmROW09? M37Tb4Rm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBIOi:PIHPlcIx{ NGHIc2EyQDd6N{izNi=>
MHG-U1 NUHGVHJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljLNVDDqM7:TR?= M{KwWlI1KGh? M2DxeWROW09? M{W2SIRm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBIOi:PIHPlcIx{ MWWxPFc5Pzh|Mh?=
SMMC-7721 NWrRWWpuSXCxcITvd4l{KEG|c3H5 M2rxUVIxOMLibl2= MWeyOEBp M1T4XIlv[3KnYYPld{BEUFhvaX7keYNm\CCjcH;weI9{cXN? NUnsS3VUOTd3NUexPVE>
SMMC-7721 M{XvU2Z2dmO2aX;uJGF{e2G7 Mn\xNlAxyqCwTR?= NFvqTFMzPCCq NXvOcYZXfXBvcnXneYxifGW|IN8yNUw1T1RzIHX4dJJme3Orb36= NH3XNFYyPzV3N{G5NS=>
HeLa NHm0cVNHfW6ldHnvckBCe3OjeR?= M2qzOVExOMLibl5CpC=> Mlv1NUBp MUPhcJRmenNidHjlJI1wenCqb3zv[5khd2ZidHjlJJRz[W6|ZnXydolvKHKnY4njcIlv\yClb33wZZJ1dWWwdB?= NWjRUJNROTZ6OUC5NVU>
MRC5VI MUPGeY5kfGmxbjDBd5NigQ>? NXm4TFI2OTJwNTDtUS=> M1nVVFAvPSCq MmTsSG1UVw>? NEnxNo9i[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? MXqxOlIzPzN7NB?=
AT5BIVA MVvGeY5kfGmxbjDBd5NigQ>? Mk\YNVIvPSCvTR?= MojrNE42KGh? MXLEUXNQ NF7jblRi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? M3fWbFE3OjJ5M{m0
M059J M4H1[WZ2dmO2aX;uJGF{e2G7 NYHp[IVHOTJwNTDtUS=> NEXYe5oxNjViaB?= Mke4SG1UVw>? NVrreohO[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? MYWxOlIzPzN7NB?=
HeLa M1jyVWZ2dmO2aX;uJGF{e2G7 NXfPSY42OTJwNTDtUS=> MV:wMlUhcA>? MnzaSG1UVw>? NWfTPWRK[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? M3nDelE3OjJ5M{m0
N2a MXPBdI9xfG:|aYOgRZN{[Xl? NWX0cZpnOC5zLUGwJO69VQ>? NWXhcYhuOiCq MWLpcoR2[2W|IHTlZ5Jm[XOnZDDj[YxtKH[rYXLpcIl1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MkLXNVU5PDJ5Nke=
Jurkat  NYTWS2pnU2mwYYPlJGF{e2G7 NWH2RY1RUUN3MDDv[kAzPCCwTR?= MYCxOVY3PDVzOR?=

... Click to View More Cell Line Experimental Data

In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
+ Expand
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Formulation: Dissolved at 0.4 mg/mL in DMSO, and diluted with 0.9% NaCl before use
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
in solvent
Synonyms KY 12420

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID